Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.
Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.
复制标题
RRx-001 和重新引入铂双药治疗后前列腺转移性去势抵抗性神经内分泌癌的完全代谢反应。
DOI：
10.1002/ccr3.1880
复制
发表时间：
2018
影响因子：
0.7
通讯作者：
Brzezniak,Christina
中科院分区：
文献类型：
--
作者：
Ojemuyiwa,Michelle;Zeman,Karen;Spira,Alexander;Oronsky,Bryan;Ray,Carolyn;Trepel,JaneB;Lee,Min-Jung;Onyiuke,Ifeyinwa;Brzezniak,Christina
本文提供的关键临床信息是一名接受过大量预治疗的高级别神经内分泌前列腺癌患者的病例，该患者在II期临床试验中接受CD-47和SIRP-α双重抑制剂RRx-001治疗后，接受铂类化疗后实现了完全代谢缓解。
Key Clinical Message Presented herein is the case of a heavily pretreated patient with high‐grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum‐based chemotherapy after treatment with the dual CD‐47 and SIRP‐α inhibitor, RRx‐001, in a Phase II clinical trial.